Exelixis, Inc.

EXEL · Nasdaq · ·

तुलना करें

$68.99-1.2%13 नव॰ बंद भाव

2 अक्टूबर 2026 तक के आँकड़े, 29 अक्टूबर 2026 को दाखिल 10-Q से

1W: -0.8%
1M: +9.8%

Exelixis, Inc. (EXEL) शेयर — क्या यह अच्छा व्यवसाय है? — InspectStocks

Exelixis, Inc.

EXEL · Nasdaq · ·

तुलना करें

$68.99-1.2%13 नव॰ बंद भाव

2 अक्टूबर 2026 तक के आँकड़े, 29 अक्टूबर 2026 को दाखिल 10-Q से

1W: -0.8%
1M: +9.8%

Just reported

Q3 FY2027 results

From Exelixis's results release of 29 अक्टूबर 2026; its quarterly report has since been filed.

Revenue
Actual
$658.7M
+10% y/y
+4.8% q/q
Guided
—
No guide given
EPS, GAAP
Actual
$0.85
+23% y/y
+3.7% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
$268.4M
+13% y/y
+8.1% q/q
Guided
—
No guide given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Exelixis is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

चयनित
Biotech
InspectStocks द्वारा · 19 companies
Drug developers with approved medicines, built mainly on biologic and genetic science.
भाव, 1 वर्ष
+26.8%
राजस्व, 1 वर्ष
+12.9%
+13
A 8B 4C 5D 1F 1

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 355 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

कमाई कैसे होती है

Cabometyx sales38%
Cometriq sales0%
License revenue4%
Collaboration revenue4%

आमदनी के हिस्से year ended 2025-12-31 के अनुमान हैं, किसी दाख़िल रिपोर्ट के आँकड़े नहीं।

मुकाबला किनसे है

क्या बेचती है6

CABOMETYX (cabozantinib) tablets
A cancer medicine used alone for several cancers, including kidney, liver, thyroid and neuroendocrine cancers, and with nivolumab for some kidney cancers.
COMETRIQ (cabozantinib) capsules
A cabozantinib medicine for progressive, metastatic medullary thyroid cancer.
COTELLIC (cobimetinib)
A medicine used in combination treatments for certain forms of advanced melanoma; Genentech markets it under a collaboration with Exelixis.

3 और दिखाएँ

MINNEBRO (esaxerenone)
A medicine for high blood pressure in Japan, licensed to Daiichi Sankyo.
Zanzalintinib
An experimental cancer medicine being tested alone and with other medicines. Exelixis has applied for U.S. approval of its use with atezolizumab for previously treated metastatic colorectal cancer.
XL309
An experimental medicine being tested in people with advanced solid tumors, alone and with a drug that blocks PARP, a protein involved in cell repair.

कौन खरीदता है4

U.S. wholesalers and specialty pharmacies buy Cabometyx and Cometriq and may resell them to hospitals and other organizations that provide the medicines to patients.
Oncologists and other healthcare professionals prescribe and help patients obtain the medicines; Exelixis also provides reimbursement assistance and patient support.
Ipsen sells cabozantinib outside the United States and Japan and pays Exelixis royalties; Takeda sells it in Japan and pays Exelixis royalties.
Genentech markets Cotellic under a collaboration with Exelixis, and Daiichi Sankyo holds the license for Minnebro.

किस पर टिका है, और क्या इसे तोड़ सकता है

कारोबार किन चीज़ों पर टिका है

1Cabometyx accounts for most of the company’s revenue, so sales depend substantially on physicians choosing it and patients continuing treatment.
2Ipsen handles cabozantinib commercialization outside the United States and Japan, and Takeda handles it in Japan; Exelixis does not control the amount or timing of their commercial investment.
3Exelixis relies on outside manufacturers to make its medicines and drug candidates, and on outside logistics providers to store and ship its U.S. commercial products.
4Sales depend on government and private health plans covering the medicines and reimbursing their cost; U.S. drug-pricing rules and other government measures can affect that coverage and reimbursement.

क्या ग़लत हो सकता है

1Cabometyx faces competing cancer treatments, and lower physician or patient use could reduce the sales on which Exelixis relies.
2Generic and follow-on cabozantinib products could reduce Cabometyx revenue; the timing of their entry depends on regulatory decisions, patent disputes and settlement terms.
3Clinical trials or regulatory reviews may not lead to approval of new uses or new medicines, including zanzalintinib; even if approved, doctors and payers may not adopt or cover them.

पूरे वित्तीय विवरण →

Exelixis, Inc. के बारे में

Exelixis’s main medicine is Cabometyx, a tablet used to treat several cancers, including kidney cancer; it is also used with Bristol Myers Squibb’s nivolumab for some patients. Exelixis sells Cabometyx and Cometriq in the United States, while Ipsen and Takeda sell cabozantinib in other countries and pay Exelixis royalties. The company also earns money from licensing and collaborating on other medicines, including Cotellic and Minnebro, and is developing cancer drug candidates such as zanzalintinib. The U.S. Food and Drug Administration is reviewing zanzalintinib with atezolizumab for previously treated colorectal cancer.

मुख्यालय: Alameda, California, United States
स्थापना: 1994
सूचीबद्ध: NASDAQ
वित्त वर्ष का अंत: 52- or 53-week year ending on the Friday closest to December 31

Exelixis, Inc. की अपनी रिपोर्टों से बना, जो अमेरिकी प्रतिभूति और विनिमय आयोग (SEC) में दाखिल की गईं। आँकड़े जैसे बताए गए, और प्रति-शेयर इतिहास आज के शेयर आधार पर पुनर्गणित। यह एक व्यवसाय का वर्णन है — यह निवेश सलाह नहीं है और न ही कुछ खरीदने या बेचने की सिफ़ारिश।

Just reported

Q3 FY2027 results

From Exelixis's results release of 29 अक्टूबर 2026; its quarterly report has since been filed.

Revenue
Actual
$658.7M
+10% y/y
+4.8% q/q
Guided
—
No guide given
EPS, GAAP
Actual
$0.85
+23% y/y
+3.7% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
$268.4M
+13% y/y
+8.1% q/q
Guided
—
No guide given